Gentian Diagnostics AS (FRA:6FK) LT-Debt-to-Total-Asset: 0.08 (As of Jun. 2026)

What is Gentian Diagnostics AS LT-Debt-to-Total-Asset?

Gentian Diagnostics AS FRA:6FK +3.58% 73 LT-Debt-to-Total-Asset is 0.08 as of Jun. 2026. GuruFocus rates FRA:6FK with a GF Score™ of 73/100 and a GF Value™ of €5.19 (Significantly Undervalued).

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Gentian Diagnostics AS's long-term debt to total assests ratio for the quarter that ended in Jun. 2026 was 0.08.

Gentian Diagnostics AS's long-term debt to total assets ratio increased from Jun. 2025 (0.01) to Jun. 2026 (0.08). It may suggest that Gentian Diagnostics AS is progressively becoming more dependent on debt to grow their business.

Gentian Diagnostics AS (FRA:6FK) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Gentian Diagnostics AS LT-Debt-to-Total-Asset Related Terms

Gentian Diagnostics AS LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Gentian Diagnostics AS's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gentian Diagnostics AS LT-Debt-to-Total-Asset Chart

Gentian Diagnostics AS Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.07

0.06

0.05

0.02

0.08

Gentian Diagnostics AS Quarterly Data
	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26	Jun26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.01	0.01	0.08	0.08	0.08

73GF Score

Gentian Diagnostics AS FRA:6FK

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Gentian Diagnostics AS LT-Debt-to-Total-Asset Calculation

Gentian Diagnostics AS's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	1.643	/	21.846
	=	0.08

Gentian Diagnostics AS's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2026 is calculated as

LT Debt to Total Assets (Q: Jun. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2026 )	/	Total Assets (Q: Jun. 2026 )
	=	1.523	/	20.244
	=	0.08

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.08 mean?

Gentian Diagnostics AS (FRA:6FK) has a LT-Debt-to-Total-Asset of 0.08 as of Jun. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Gentian Diagnostics AS and its competitors.

Is Gentian Diagnostics AS's LT-Debt-to-Total-Asset too high?

Gentian Diagnostics AS's current LT-Debt-to-Total-Asset is 0.08. Overall, Gentian Diagnostics AS has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Gentian Diagnostics AS's LT-Debt-to-Total-Asset compare to ABT and SYK?

Gentian Diagnostics AS's LT-Debt-to-Total-Asset of 0.08 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?

A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Gentian Diagnostics AS and its competitors. Gentian Diagnostics AS's current LT-Debt-to-Total-Asset is 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Gentian Diagnostics AS stock overvalued right now?

Based on GuruFocus' analysis, Gentian Diagnostics AS (FRA:6FK) is currently considered Significantly Undervalued. The stock's GF Value™ is €5.19, compared to a current price of €3.47 — trading 33.1% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.08. Gentian Diagnostics AS's overall GF Score™ is 73/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Gentian Diagnostics AS (FRA:6FK), the current LT-Debt-to-Total-Asset is 0.08 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gentian Diagnostics AS (FRA:6FK) Overvalued in 2026?

Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued. The current stock price of €3.47 is trading 33.1% below its estimated GF Value™ of €5.19. GuruFocus considers Gentian Diagnostics AS to be Significantly Undervalued.

Key valuation signals for FRA:6FK:

LT-Debt-to-Total-Asset: 0.08
GF Value™: €5.19 vs. price of €3.47 (33.1% below fair value)
GF Score™: 73/100

No single metric tells the full story. See the FRA:6FK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gentian Diagnostics AS Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies OSL:OBSRV OSL:LIFE ABT SYK MDT BSX EW XTER:SHL GEHC DXCM XAMS:PHIA SZSE:300760 STE ZBH XSWX:SOON LSE:SN.PEN SHSE:688271 GMED TSE:7733

Other Exchanges GENTOo:Sweden GENT:Norway

Address Bjornasveien 5, Moss, NOR, 1596

Website https://www.gentian.com

Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.

73GF Score

Get the complete analysis for FRA:6FK

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.47

Price

€5.19

GF Value

View FRA:6FK Analysis

See LT-Debt-to-Total-Asset data for all stocks →